Clinical Report: Dysfunction and Exhaustion of Regulatory T Cells in Uveitis

Overview

This review highlights the critical role of regulatory T cells (Tregs) in maintaining ocular homeostasis in non-infectious uveitis and discusses their dysfunction and exhaustion across various subtypes. It emphasizes the immunometabolic factors and environmental influences that contribute to Treg instability and outlines novel therapeutic approaches aimed at restoring Treg competence.

Background

Non-infectious uveitis is a significant cause of visual impairment and blindness, affecting individuals of working age and imposing socio-economic burdens. The condition is characterized by a breakdown of immune tolerance, with Tregs playing a vital role in suppressing inappropriate immune responses. Understanding Treg dysfunction is essential for developing targeted therapies to manage this complex disease effectively.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Tregs are crucial for maintaining ocular homeostasis and preventing tissue damage in uveitis.
• Behçet’s disease, VKH disease, and HLA-B27-associated uveitis exhibit distinct patterns of Treg dysfunction.
• Intrinsic factors such as FoxP3 stability and upregulation of inhibitory checkpoints contribute to Treg exhaustion.
• Extrinsic factors, including A2Ar signaling and gut microbiota, significantly influence Treg functionality.
• Novel therapeutic strategies include immune checkpoint agonists and metabolic reprogramming agents like Itaconate.

Clinical Implications

Clinicians should consider the subtype-specific mechanisms of Treg dysfunction when developing treatment plans for non-infectious uveitis. Emerging therapies aimed at restoring Treg function may offer new avenues for managing this challenging condition.

Conclusion

The review underscores the importance of understanding Treg dynamics in uveitis and highlights potential therapeutic strategies that could improve patient outcomes. Continued research is essential to translate these findings into clinical practice.

References

1. Retinal Physician, UVEITIS CORNER: Recent and Current Clinical Trials in Uveitis, 2019 -- New targets and mechanisms are being evaluated.
2. Retinal Physician, Immunosuppressive Therapy for Noninfectious Uveitis, 2007 -- Ocular inflammatory diseases are a significant cause of visual impairment.
3. Retinal Physician, Immunomodulatory Therapy in Noninfectious Posterior Uveitis, 2012 -- Four therapies from which to choose.
4. Ophthalmology Management, Systemic therapy for non-infectious uveitis, 2018 -- Overview of systemic therapy approaches.
5. Recommendations Management | EULAR -- Guidelines for managing uveitis.
6. Adalimumab in Patients with Active Noninfectious Uveitis
7. Regulatory T Cell Dysfunction and Exhaustion in Uveitis: Immunometabolic Mechanisms, Microenvironmental Drivers, and Emerging Therapeutic Strategies
8. Recommendations Management | EULAR